Sertraline and fluoxetine are selective serotonin re-uptake inhibitors (SSRIs) that are widely prescribed to treat depression. They exert their effects by inhibiting the presynaptic plasma membrane serotonin transporter (SERT). All SSRIs possess halogen atoms at specific positions, which are key determinants for the drugs' specificity for SERT. For the SERT protein, however, the structural basis of its specificity for SSRIs is poorly understood. Here we report the crystal structures of LeuT, a bacterial SERT homolog, in complex with sertraline, R-fluoxetine or S-fluoxetine. The SSRI halogens all bind to exactly the same pocket within LeuT. Mutation at this halogen-binding pocket (HBP) in SERT markedly reduces the transporter's affinity for SSRIs but not for tricyclic antidepressants. Conversely, when the only nonconserved HBP residue in both norepinephrine and dopamine transporters is mutated into that found in SERT, their affinities for all the three SSRIs increase uniformly. Thus, the specificity of SERT for SSRIs is dependent largely on interaction of the drug halogens with the protein's HBP.
SSRIs bind directly to the serotonin-transporter protein and inhibit neurotransmitter recycling, making them effective drugs for the treatment of depressive disorders 1, 2 . SSRIs, however, are rather promiscuous in that they also bind to the homologous norepinephrine and dopamine transporters (NET and DAT, respectively), although with much lower affinity than to their principal target, SERT 3, 4 . The selectivity of SSRIs for SERT is intriguing. Merely one or two different functional group substitutions are sufficient to convert an SSRI into a norepinephrine-reuptake inhibitor (NRI) with higher affinity to NET [5] [6] [7] . It is recognized that both the position and type of substitution on an aromatic moiety of the SSRI molecule are important for the higher specificity to SERT 8, 9 . In particular, halogen substitutions on this ring are found to be largely responsible for SSRIs' specificity to SERT 5, 6, 10 . On the protein side, however, the transporter-SSRI interactions that define the specificity of SERT for these drugs have not yet been described, which hinders the development of more specific antidepressants 11 .
The human SERT, NET and DAT proteins are all members of the neurotransmitter:sodium symporter (NSS) family [12] [13] [14] . The same protein family also contains members from bacterial cells, and such proteins often function as amino acid transporters 15 . One family member is the leucine transporter LeuT from Aquifex aeolicus. LeuT shares 20-25% identity in primary sequence with the human neurotransmitter transporters, and the crystal structure of LeuT 16 and its transport mechanism have proven to be good model systems for the study of mammalian NSS proteins [17] [18] [19] [20] . To understand the structural basis of the serotonin transporter's specificity for SSRIs, we carried out crystallographic studies of the bacterial leucine transporter LeuT in complex with three different SSRIs. This was followed by mutagenesis and pharmacological studies of the human SERT, NET and DAT proteins at the equivalent drug-binding site.
RESULTS
We first showed that three SSRIs-sertraline, R-fluoxetine and S-fluoxetine-all bind to LeuT (Fig. 1a) and that they also inhibit substrate transport by the protein reconstituted into proteoliposomes (Fig. 1b) . We then cocrystallized LeuT with either sertraline, R-fluoxetine or S-fluoxetine (Prozac contains equal amounts of the R-and S-enantiomers, both pharmacologically active), along with substrate leucine and sodium ions, and determined these complex structures at a resolution of 2.15 Å , 2.35 Å and 2.45 Å , respectively ( Table 1 and Supplementary Fig. 1a online) . In all these crystals the overall structure of the protein-substrate complex is similar to that of the drug-free form 16 . However, in all three complexes, we observed a strong electron-density peak in the vestibule between the tip of the extracellular loop EL4 and the extracellular gate ( Fig. 1c and Supplementary Fig. 1a) , which is formed by residues Arg30, Asp404, Tyr108 and Phe253. The density was assigned to sertraline, R-fluoxetine and S-fluoxetine, respectively (Figs. 1d-f ). This drug binding location is similar to the tricyclic antidepressant (TCA)-binding site in LeuT 21, 22 , and no secondary SSRI-binding site was found in the protein.
Sertraline-binding site in LeuT
Although the position of binding to the protein is similar to that observed for TCAs, how the SSRIs bind to the protein is markedly different. In the LeuT-sertraline structure, the drug molecule binds to the extracellular vestibule in the protein in such a way that the two chlorine atoms on the phenyl ring insert into a pocket that is formed by Leu25, Gly26, Leu29, Arg30, Tyr108, Ile111 and Phe253 (Fig. 1d) , and they make additional van der Waals contact with Leu29, Tyr108 and Phe253 ( Fig. 2a and Supplementary Fig. 2a  online) . The amino acid sequence in this HBP is highly conserved between LeuT and SERT. Notably, four of the halogen-binding residues, Leu25, Gly26, Tyr108 and Phe253, also interact at the opposite side of the polypeptide chain with the leucine (Supplementary Fig. 1b ) or another bound substrate 23 , demonstrating that the drug-binding site and the substrate-binding site, although not sharing the same physical space, do share several common amino acid residues. At the other end of the sertraline molecule, the dichlorophenyl ring is approximately perpendicular to the tetrahydronaphthalene ring, which is tilted slightly from the membrane plane. In addition to being in contact with Leu400, Asp401 and Asp404 of transmembrane a-helix 10 (TM10), the tetrahydronaphthalene rings interact with residues Ala319 of the EL4 hairpin loop and Arg30 and Gln34 of TM1, whereas the amine tail points toward the cytoplasm. Notably, the amine nitrogen forms a salt bridge (named salt bridge 1) with the carboxyl group of Asp404 (Fig. 2b) and, simultaneously, interacts with the backbone oxygen of Asp401 via a bound water molecule. Another water molecule, located in the same position between Arg30 and Asp404 as one observed in the drug-free structure of LeuT 16 , mediates the two residues' interactions with the SSRI. The bound sertraline molecule itself has its dichlorophenyl ring rotated about the C4-C13 bond by 1801 ( Supplementary Fig. 3a online) compared to the free drug 24 . Otherwise, the sertraline molecule is rather rigid, indicating that the drug maintains its low-energy configuration upon binding to its protein target.
R-fluoxetine-binding site in LeuT R-fluoxetine binds to the same extracellular vestibule in LeuT as sertraline (Fig. 1e) . The halogen atoms (in this case three fluorines of the methylphenoxy ring) insert into the same HBP as the two sertraline chlorines, making contact with Leu25, Gly26, Leu29, Arg30 and Tyr108 ( Fig. 2a and Supplementary Fig. 2b ). At the opposite end of the R-fluoxetine molecule, the phenyl ring is surrounded by Ala319 and Phe320 from the tip of the EL4 hairpin and Leu400 and Asp401 from TM10 on the extracellular side. Similarly to sertraline, the amine tail in R-fluoxetine points toward the cytoplasm and interacts with Gln34 via a bound water molecule. As observed in the LeuT-sertraline structure, a water molecule, located between Arg30 and Asp404, mediates interaction of these two residues with the methylphenoxy ring of the drug (Fig. 1e) . In this LeuT-bound form, the same ring rotates about the O5-C6 bond by 461 compared to that of the free drug 25 ( Supplementary Fig. 3b ).
S-fluoxetine-binding site in LeuT
The fluorine atoms on the phenoxy ring of S-fluoxetine also insert into the same HBP in LeuT (Fig. 1f) , making van der Waals contact with Leu25, Gly26, Leu29, Arg30, Tyr108 and Phe253 (Fig. 2a,c ).
As observed in the LeuT-sertraline and LeuT-R-fluoxetine complexes ( Supplementary Fig. 1b ), Leu25, Gly26, Tyr108 and Phe253 are shared between the drug-binding site and the substrate-binding site.
In contrast to R-fluoxetine, however, due to its opposite chirality, the rest of the S-fluoxetine molecule is reversed in the binding pocket, with the phenyl ring interacting with the gate, the amine tail pointing to the extracellular space and the nitrogen atom of the amine group forming a salt bridge (named salt bridge 2) with Asp401 (Figs. 1f and 2b). Moreover, the Arg30 side chain flips toward Asp404, forming a salt bridge with it. As a result, both the S-fluoxetine rings, the positively charged guanidinium group of Arg30 and the phenyl ring of Phe253 form a stable cation-p cluster similar to that observed in the LeuT-TCA complexes 21, 22 . As with R-fluoxetine, the methylphenoxy ring of S-fluoxetine rotates about the O5-C6 bond upon binding to LeuT, but by a smaller angle (191) ( Supplementary Fig. 3c ). because of the positively charged amine group and the electronegative halogen atoms, points in approximately the same direction, from TM10 to TM1. Not only are the dichlorophenyl group of sertraline and the trifluoromethylphenoxy groups of both fluoxetine enantiomers roughly superimposable, but all three SSRIs have their halogen atoms inserted into the same HBP in LeuT and interact with the same residues (Fig. 2a) . Conversely, the difference in their binding lies with the manner in which the other parts of the molecules interact with the protein-the amine group points either toward the extracellular space and interacts with the N-terminal end of TM10 (for S-fluoxetine), or toward the cytoplasm where it interacts with the extracellular gate of the transporter (for sertraline and R-fluoxetine) (Fig. 2b) . Although both R-fluoxetine and S-fluoxetine show certain degrees of flexibility, the structure of the protein itself in all the three LeuT-SSRI complexes is also rather rigid: besides the rotation of Arg30 in the LeuT-S-fluoxetine complex, only the side chains of Gln34, Ala319, Phe320, Leu400 and Asp401 shift slightly upon drug binding (Supplementary Fig. 4 online) .
Common features of SSRI binding to LeuT
It is notable that all the shared key features of SSRI molecules are important for binding to LeuT (Fig. 1) . The observation that halogensubstituted phenyl rings and particularly the halogen atoms themselves-the most important determinants for SSRI specificity-bind at the same position in LeuT (Fig. 2) immediately suggests that in the human SERT these SSRIs may also bind both at the same position and in a similar manner. Whereas the other parts of the drug molecules are likely to bind to SERT in different ways given the diversity in their molecular structures, the binding site for their halogen atoms is invariant. Indeed, amino acids around the presumed extracellular vestibule in the human serotonin transporter SERT are largely homologous with those in LeuT, particularly within the HBP (Figs. 2a,c and  3a,b) , where six of the seven residues (Leu99, Gly100, Arg104, Tyr176, Ile179 and Phe335 in SERT) are conserved; only Trp103 (Leu29 in LeuT) is not.
SSRI binding to SERT mutants
We tested our hypothesis of conservation of both the position and the mode of SSRI binding between SERT and LeuT by performing mutagenesis around the tentative SSRI-binding site in the human protein, followed by two types of independent measurements using uptake ( Table 2 ) and binding inhibition assays (Fig. 3) in HEK293 cells. On the basis of a homology model of SERT 18 , we chose three areas for investigation that are nonlinear in three-dimensional space. We first focused on the HBP. Ile179 in SERT (Ile111 in LeuT) was examined for its charge and size: when mutated to alanine, phenylalanine or aspartate, there was a strong reduction in the protein's affinity to sertraline, as measured by transport inhibition, with increases in the affinity measurement IC 50 ranging from 1,080-fold for I179F to 310-fold for I179A ( Table 2) . Such observed changes in SERT affinity are as large as previously reported for other mutants [26] [27] [28] . For two of our mutants (I179A and I179D) the affinities for R-and S-fluoxetines also decreased, although less substantially (by 7-fold to 20-fold) ( Table 2) . Mutations in two residues near the HBP also reduced the affinity of SERT to sertraline. Mutation of Tyr175 to a negatively charged glutamate caused an eight-fold decrease in affinity, and Ile108 when mutated to a leucine (as found in the DAT sequence) yielded a 180-fold lower affinity. We chose one of these mutants, I179D, and further tested how it affected SERT's affinity for sertraline using a binding assay. This mutation at the HBP was found to strongly reduce the protein's affinity to sertraline (Fig. 3c, Table 2 and Supplementary Fig. 5a -c online) but had no effect on the affinities to the TCAs clomipramine (with a halogen substitution at a different position, Supplementary Fig. 6 online) or desipramine (without halogen substitution). These results strongly support our hypothesis that it is indeed the halogen atoms in SSRIs that bind to the HBP site. The larger changes in affinity to sertraline than the fluoxetines observed in our work are probably due to the fact that the chlorine substitutions in sertraline are much more rigid with respect to the phenyl ring than the trimethylfluorine substitution in fluoxetines 25 ( Supplementary Fig. 3 ), and are therefore much less adaptive to changes in the HBP. The above hypothesis also agrees with previous mutagenesis experiments on SERT where the G100A and T178A mutatations at the HBP reduced affinity of the protein to citalopram 29 . The mutation of Gly100 to the larger alanine, the residue found in the NET and DAT sequences, probably interferes with interactions between the citalopram fluorine and the HBP. This explains why an SSRI does not bind as tightly to NET or DAT.
We next investigated SERT-SSRI interaction at the salt bridge 1 region because the aspartate residue for salt bridge 2 is not conserved in SERT. In LeuT, the gate residue Asp404 forms an ion pair with the amine nitrogen in sertraline (Figs. 1d and 2b) and it also interacts with the amine nitrogen atom in R-fluoxetine via a bound water molecule (Fig. 1e) . The amine nitrogen atom in S-fluoxetine, in contrast, points toward the extracellular space (Fig. 1f) . When the equivalent gate residue in the salt bridge 1 region in SERT, Glu493, was mutated to another acidic amino acid, aspartate, its affinity to the three SSRIs in uptake assays changed little; when this residues was mutated to an uncharged glutamine, however, the protein's affinity to sertraline and R-fluoxetine was reduced by 15-fold and 3-fold, respectively. As expected, the affinity to S-fluoxetine, which has an amine group that points toward to the extracellular space, did not change. These results are consistent with the idea that sertraline and R-fluoxetine, but not S-fluoxetine, interact strongly with the gate residue Glu493, as was observed for the LeuT-SSRI complexes.
The third region examined was the N-terminal end of TM10 and the tip of the EL4 hairpin, both on the extracellular side of the bound drugs. When Lys490 in SERT was mutated to a threonine (as found in the NET and DAT sequences), the protein's affinity to sertraline decreased by close to 100-fold ( Table 2 ). Mutations at the adjacent residue, V489F and V489L (phenylalanine is found in DAT and leucine in NET), reduced the affinities of SERT to sertraline by 16-fold and 3-fold, respectively. Similarly, when Ala401 in SERT was deleted to make the EL4 hairpin tip more like that of the NET and DAT sequences of at least three experiments. The significance of measurements are indicated by * (P r 0.05) and ** (P r 0.005) compared with the wild-type value (one-way analysis of variance, followed by the Holm-Sidak multiple comparisons test).
( Supplementary Fig. 7 online) , SERT bound sertraline with a 210-fold lower affinity. Concomitantly, we observed little or no change in affinity for R-or S-fluoxetine in these mutants. These results indicate the rigid three-ringed sertraline molecule interacts directly with the N-terminal end of TM10 and the EL4 hairpin tip, whereas the tworinged R-and S-fluoxetines probably bind more deeply, toward the gate residues in SERT. The above experimental results on three nonlinear areas in the extracellular vestibule of SERT strongly suggest that SSRIs bind to the same site in the human serotonin transporter, as found in LeuT.
SSRI binding to NET and DAT mutants
Human SERT binds SSRIs with much greater affinity than either NET or DAT does, underlining the specificity of SERT for these antidepressants. The only difference in primary sequence at the HBP between SERT and NET or DAT is at Gly100 in SERT (Fig. 3a,b) , which is an alanine in the other two proteins. If the HBP has a key role in determining SERT's specificity for SSRIs, our model predicts explicitly that mutation of the alanine to glycine at that position in both NET and DAT would substantially increase their affinities for SSRIs. As that glycine residue is essential and its mutation abolished the proteins' transport activity 29 , to verify the above prediction we measured the SSRI affinities using binding assays. The validity of such a binding assay has been shown previously 4, 30 and reiterated here by the agreement between the results of transport-inhibition assays and binding assays for the I179D SERT mutant ( Fig. 3c and Table 2) . Notably, when the key alanine in the HBP was mutated to a glycine as found in the SERT sequence (Fig. 3a,b) , the human NET-A77G construct showed markedly increased affinities to all three SSRIs tested in binding assays. The IC 50 values for sertraline, R-fluoxetine and S-fluoxetine decreased to 55%, 51% and 43%, respectively, of that of the wild-type NET (Fig. 3d, Table 2 and Supplementary Fig. 5d-f) . Similarly, for the human DAT protein, the A81G mutation reduced its IC 50 values for sertraline, R-and S-fluoxetine, to 26%, 43% and 35% of the respective wild-type values (Fig. 3e, Table 2 and Supplementary Fig. 5g-i) . Such gain-of-function mutagenesis results are in total agreement with the prediction made by our model. The fact that when both NET and DAT, the very neurotransmitter transporters that SSRIs are developed to select against, showed such uniformly increased affinities for all three SSRIs tested when their HBP was mutated to that of the SERT sequence, strongly suggests that the HBP in SERT is directly involved SSRI binding and functions as one key determinant for this protein's antidepressant specificity.
DISCUSSION SSRI binding and TCA binding to LeuT
Previously it has been observed that tricyclic antidepressants bind to the extracellular vestibule and it is this binding that inhibits transport 21, 22 . Now we have shown that three different SSRI molecules can bind to the same position. However, the interactions of SSRIs with LeuT are very different from those of TCAs. Although the TCA amine group is located at the same position as that in S-fluoxetine and also interacts with Asp401 ( Supplementary Fig. 6a) , none of the three rings of any TCA possess substitutions that penetrate into the HBP; the chlorine atom on clomipramine, a TCA that has a much higher affinity to SERT than to NET 3 , points in a different direction rather than inserting itself into the HBP (Supplementary Fig. 6b ). Similar to TCAs bound to LeuT 21, 22 , the sertraline molecule, which possesses three rings as opposed to the two found in the fluoxetines, displays higher structural rigidity ( Supplementary Fig. 3 ). The agreement of position of the SSRI-binding site with the TCA-binding site indicates a common inhibition mechanism of transport 21, 22 . In contrast to the binding of a second substrate at this vestibule, which triggers the cytoplasmic release of the substrate at the primary site 31, 32 , TCAs and SSRIs bind to distinct regions of the vestibule and prevent substrate release by stabilizing the so-called occluded conformation (Supplementary Figs. 1b and 6 ). This manner of inhibition differs from that by tryptophan, which binds at the primary leucine site 23 .
SSRI halogens and the HBP
The common features of the binding of all three SSRIs to LeuT, particularly the superposition of their halogen atoms in the overlapping halogen-substituted phenyl ring, are clearly reminiscent of previously well characterized determinants of antidepressant specificity-key features that make an SSRI specific for SERT versus those that make an NRI specific for NET. All SSRIs have a halogen substitution at the third or fourth position of the phenyl or phenoxy ring (Fig. 2) , and it is this characteristic that seems to be largely responsible for the drugs' specificity to SERT over NET 5, 6, 8, 10 . In sertraline-related compounds, other types of halogen substitutions with Cl-or CF 3 -at one or both positions in aminotetraline also yield an SSRI 10 (Fig. 2d) . Similarly, for phenoxyphenylpropylamine derivative-based antidepressants, besides the 4-CF 3 -substitution found in R-and S-fluoxetines, other kinds of substitutions at this position (F-, Cl-, CH 3 -or OCH 3 -) also produce SSRIs 5, 6 (Fig. 2e) . In contrast, substitutions with CH 3 -or OCH 3 -at the second position in the phenoxy ring yield NRIs such as tomoxetine and nisoxetine (Fig. 2e) . As an important drug component, fluorine substituents in various drugs have been shown to be crucial for the drugs' affinity and selectivity by undergoing multipolar interactions with protein backbone in a hydrophobic environment as well as with the positively charged guanidinium side chain of arginine 33 . Not restricted to the aforementioned aminotetraline and phenoxyphenylpropylamine derivatives, substitutions with an electronegative halogen at the fourth position in the phenyl or phenoxy ring are found in every other SSRI currently on the market-CF 3 -in fluvoxamine and F-in paroxetine and citalopram 5, 7, 34 . Notably, halogen substitutions at the same ring positions are also found in serotonin-norepinephrine reuptake inhibitors (sibutramine and nefazodone) 35, 36 as well as the recently discovered serotonin-norepinephrine-dopamine triple reuptake inhibitors (brasofensine, tesofensine, indatraline and DOV21,947) [37] [38] [39] [40] but, in stark contrast, not in NRIs 8,34 .
SERT's specificity for SSRIs
Given that it is the halogen atoms of SSRIs that confer specificity of these drugs to SERT 5, 6, 10 , that structurally dissimilar SSRIs bind to the same extracellular vestibule in LeuT with their halogen atoms overlapping, that the HBP is highly conserved between LeuT and SERT, that mutations of residues in the SERT HBP result in drastic changes in affinity to SSRIs and, particularly, that uniformly significant gain-offunction data was obtained for both NET and DAT with three SSRIs, it is likely that in SERT SSRIs bind at the same extracellular vestibule as in LeuT and that the specificity of the human transporter to this class of antidepressants is defined in large part by interaction of the drug halogens with the protein's HBP. Given the size of the SSRI molecules, additional structural determinants for SERT's specificity for the drugs must also exist. Nonetheless, the better understanding of the structural basis of SERT's drug specificity provided by the current work should aid in designing more specific antidepressants.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
Accession codes. Protein Data Bank: Atomic coordinates and structure factors for LeuT-sertraline, LeuT-R-fluoxetine and LeuT-R-fluoxetine have been deposited under accession codes 3GWU, 3GWV and 3GWW.
Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
ACKNOWLEDGMENTS
We thank the staff of the X12B, X25 and X29 beamlines at the National Synchrotron Light Source in Brookhaven National Laboratory for assistance in X-ray diffraction data collection. We are grateful to L.R. Forrest 
